CD274 and thyrotoxicosis: Similarly, for thyrotoxicosis differences according to the class of ICIs had been reported, with ipilimumab having low frequencies (0.2%–1.7%), anti-PD-1/anti-PD-L1 drugs having higher frequencies (0.6%–3.7%), and combination therapy having the highest frequency (8.0%–11.1%) (1, 18, 20, 21, 22, 23).